These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 31486755)

  • 21. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
    Cox AD; Der CJ; Philips MR
    Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting KRAS mutant cancers: from druggable therapy to drug resistance.
    Zhu C; Guan X; Zhang X; Luan X; Song Z; Cheng X; Zhang W; Qin JJ
    Mol Cancer; 2022 Aug; 21(1):159. PubMed ID: 35922812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
    Chen H; Smaill JB; Liu T; Ding K; Lu X
    J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer.
    Zhu Z; Xiao S; Hao H; Hou Q; Fu X
    Curr Top Med Chem; 2019; 19(23):2176-2186. PubMed ID: 31456520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics.
    Kattan WE; Hancock JF
    Biochem J; 2020 Aug; 477(15):2893-2919. PubMed ID: 32797215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. K-Ras prenylation as a potential anticancer target.
    Baranyi M; Buday L; Hegedűs B
    Cancer Metastasis Rev; 2020 Dec; 39(4):1127-1141. PubMed ID: 32524209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understand KRAS and the Quest for Anti-Cancer Drugs.
    Han CW; Jeong MS; Jang SB
    Cells; 2021 Apr; 10(4):. PubMed ID: 33917906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discoveries in the redox regulation of KRAS.
    Kramer-Drauberg M; Ambrogio C
    Int J Biochem Cell Biol; 2021 Feb; 131():105901. PubMed ID: 33309959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kirsten Ras* oncogene: significance of its discovery in human cancer research.
    Tsuchida N; Murugan AK; Grieco M
    Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond.
    Nagasaka M; Potugari B; Nguyen A; Sukari A; Azmi AS; Ou SI
    Cancer Treat Rev; 2021 Dec; 101():102309. PubMed ID: 34715449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.
    Ricciuti B; Leonardi GC; Metro G; Grignani F; Paglialunga L; Bellezza G; Baglivo S; Mencaroni C; Baldi A; Zicari D; Crinò L
    Expert Rev Respir Med; 2016; 10(1):53-68. PubMed ID: 26714748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of Current Immunotherapies Targeting Mutated KRAS Cancers.
    Hoo WPY; Siak PY; In LLA
    Curr Top Med Chem; 2019; 19(23):2158-2175. PubMed ID: 31483231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.
    Bahrami A; Hassanian SM; ShahidSales S; Farjami Z; Hasanzadeh M; Anvari K; Aledavood A; Maftouh M; Ferns GA; Khazaei M; Avan A
    J Cell Physiol; 2018 Mar; 233(3):2058-2066. PubMed ID: 28262927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
    Nyíri K; Koppány G; Vértessy BG
    Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.
    Haider K; Sharma A; Yar MS; Yakkala PA; Shafi S; Kamal A
    Expert Opin Drug Discov; 2022 Mar; 17(3):247-257. PubMed ID: 35084268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue.
    Perurena N; Cichowski K
    Cancer Cell; 2024 Jun; 42(6):943-945. PubMed ID: 38861932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving Prospects for Targeting RAS.
    Singh H; Longo DL; Chabner BA
    J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defeat mutant KRAS with synthetic lethality.
    Pang X; Liu M
    Small GTPases; 2017 Oct; 8(4):212-219. PubMed ID: 27463838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
    Pang X; Liu M
    Chin J Cancer; 2016 Oct; 35(1):92. PubMed ID: 27793187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.